CD1d-dependent activation of NKT cells aggravates atherosclerosis

被引:265
作者
Tupin, E
Nicoletti, A
Elhage, R
Rudling, M
Ljunggren, HG
Hansson, GK
Berne, GP
机构
[1] Karolinska Hosp, Ctr Mol Med, Dept Med, S-17176 Stockholm, Sweden
[2] Inst Biomed Cordeliers, INSERM, U430, F-75006 Paris, France
[3] Inst Louis Bugnard, INSERM, U589, Toulouse, France
[4] Huddinge Univ Hosp, Karolinska Inst, Ctr Metab & Endocrinol, S-14186 Stockholm, Sweden
[5] Huddinge Univ Hosp, Karolinska Inst, Ctr Infect Med, S-14186 Stockholm, Sweden
关键词
alpha-galactosylceramide; cytokines; inflammation; apolipoprotein E; mice;
D O I
10.1084/jem.20030997
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adaptive and innate immunity have been implicated in the pathogenesis of atherosclerosis. Given their abundance in the lesion, lipids might be targets of the atherosclerosis-associated immune response. Natural killer T (NKT) cells can recognize lipid antigens presented by CD1 molecules. We have explored the role of CD1d-restricted NKT cells in atherosclerosis by using apolipoprotein E-deficient (apoE(-/-)) mice, a hypercholesterolemic mouse model that develops atherosclerosis. ApoE(-/-) mice crossed with CD1d(-/-) (CD1d(-/-) apoE(-/-)) mice exhibited a 25% decrease in lesion size compared with apoE(-/-) mice. Administration of alpha-galactosylceramide, a synthetic glycolipid that activates NKT cells via CD1d, induced a 50% increase in lesion size in apoE(-/-) mice, whereas it did not affect lesion size in apoE(-/-) CD1d(-/-) mice. Treatment was accompanied by an early burst of cytokines (IFNgamma, MCP-1, TNFalpha, IL-2, IL-4, IL-5, and IL-6) followed by sustained increases in IFNgamma and IL-4 transcripts in the spleen and aorta. Early activation of both T and B cells was followed by recruitment of T and NKT cells to the aorta and activation of inflammatory genes. These results show that activation of CD1d-restricted NKT cells exacerbates atherosclerosis.
引用
收藏
页码:417 / 422
页数:6
相关论文
共 28 条
[1]   Innate and acquired immunity in atherogenesis [J].
Binder, CJ ;
Chang, MK ;
Shaw, PX ;
Miller, YI ;
Hartvigsen, K ;
Dewan, A ;
Witztum, JL .
NATURE MEDICINE, 2002, 8 (11) :1218-1226
[2]   Pneumococcal vaccination decreases atherosclerotic lesion formation:: molecular mimicry between Streptococcus pneumoniae and oxidized LDL [J].
Binder, CJ ;
Hörkkö, S ;
Dewan, A ;
Chang, MK ;
Kieu, EP ;
Goodyear, CS ;
Shaw, PX ;
Palinski, W ;
Witztum, JL ;
Silverman, GJ .
NATURE MEDICINE, 2003, 9 (06) :736-743
[3]   Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis [J].
Boring, L ;
Gosling, J ;
Cleary, M ;
Charo, IF .
NATURE, 1998, 394 (6696) :894-897
[4]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[5]   Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice [J].
Caligiuri, G ;
Rudling, M ;
Ollivier, V ;
Jacob, MP ;
Michel, JB ;
Hansson, GK ;
Nicoletti, A .
MOLECULAR MEDICINE, 2003, 9 (1-2) :10-17
[6]   NKT cell subsets in infection and inflammation [J].
Chan, WL ;
Pejnovic, N ;
Liew, TV ;
Lee, CA ;
Groves, R ;
Hamilton, H .
IMMUNOLOGY LETTERS, 2003, 85 (02) :159-163
[7]   ENDOTHELIAL EXPRESSION OF A MONONUCLEAR LEUKOCYTE ADHESION MOLECULE DURING ATHEROGENESIS [J].
CYBULSKY, MI ;
GIMBRONE, MA .
SCIENCE, 1991, 251 (4995) :788-791
[8]   The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice [J].
Davenport, P ;
Tipping, PG .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (03) :1117-1125
[9]   Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein [J].
Fujii, S ;
Shimizu, K ;
Smith, C ;
Bonifaz, L ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (02) :267-279
[10]   NKT cells: facts, functions and fallacies [J].
Godfrey, DI ;
Hammond, KJL ;
Poulton, LD ;
Smyth, MJ ;
Baxter, AG .
IMMUNOLOGY TODAY, 2000, 21 (11) :573-583